內分泌檢測市場：商業機會、成長要素、產業趨勢分析及2026-2035年預測

全球內分泌檢測市場預計到 2025 年價值 34 億美元，預計到 2035 年將以 8.2% 的複合年成長率成長至 74 億美元。

由於荷爾蒙失調（包括代謝性疾病和內分泌相關疾病）負擔日益加重，以及人們對早期診斷和預防醫學的認知不斷提高，內分泌檢測行業正穩步擴張。對定期篩檢和疾病監測的日益重視推動了醫療保健系統對診斷檢測的採用。此外，政府透過資助計畫和醫療保健舉措的持續支持，增強了檢測的可及性並改善了基礎設施。醫療保健支出的成長和診斷技術的進步進一步提高了檢測的準確性和效率。自動化系統的引進和檢查室能力的提升，使得檢測結果的快速交付和大規模檢測成為可能。對個人化醫療和長期疾病管理的日益關注，也促進了對內分泌診斷的持續需求。這些因素共同推動了已開發經濟體和新興經濟體內分泌檢測市場的穩定成長。

內分泌檢測是指一系列基於實驗室的檢查室程序，用於評估人體荷爾蒙平衡和腺體功能。這些檢測測量荷爾蒙水平和相關生物標記物，以輔助診斷和後續觀察內分泌疾病。對醫療基礎設施和公共衛生計畫的投入不斷增加，正在改善人們獲得診斷服務的途徑，尤其是在資源匱乏的地區。人們對早期檢測和預防醫學的日益關注，正在推動荷爾蒙檢測在醫療機構中的應用。政府主導的篩檢計畫和對診斷檢查室的資助也促進了檢測服務的擴展，並推動了整體市場的成長。

預計到2025年，人類絨毛膜促性腺激素分泌(hCG) 檢測市佔率將達到31.1%。該細分市場之所以能保持主導廣泛的臨床應用以及對快速、微創診斷方法日益成長的需求。醫療機構中大量的檢測以及對便利診斷方案的強勁需求，也持續支撐著該細分市場在內分泌檢測市場的主導地位。

預計到2035年，免疫檢測市場將以7.7%的複合年成長率成長，達到28億美元。該技術因其高靈敏度、高準確性和具成本效益而備受青睞。與自動化系統的兼容性以及處理大批量檢測的能力是其應用的關鍵促進因素。技術的不斷進步和診斷檢查室的廣泛認可進一步鞏固了其在市場中的重要性。

預計到2025年，北美內分泌檢測市場規模將達到15億美元，並在整個預測期內保持顯著成長。該地區受益於完善的醫療保健基礎設施、對先進診斷技術的積極應用以及對常規和專科檢測的旺盛需求。不斷提高的健康意識、完善的醫保報銷機制以及先進診斷平台的普及，持續推動全部區域檢測需求的穩定成長。

目錄

第1章：調查方法

• 研究途徑
• 品質改進計劃
  • GMI人工智慧政策及對資料完整性的承諾
    • 資訊來源一致性協議
• 調查過程和可靠性評分
  • 研究路徑的組成部分
  • 評分組成部分
• 數據收集
  • 主要來源部分列表
• 資料探勘資訊來源
  • 付費資訊來源
    • 區域資訊來源
• 基本估算和計算方法
  • 基準年的計算
• 預測模型
  • 量化市場影響分析
    • 生長參數對預測的數學影響
• 關於調查透明度的補充信息
  • 資訊來源歸屬框架
  • 品質保證指標
  • 對信任的承諾

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 糖尿病、甲狀腺疾病和肥胖症的盛行率增加。
    • 內分泌疾病盛行率增加
    • 政府扶持性經費措施
    • 技術進步
    • 人們對常規健康監測的意識日益增強
  • 產業潛在風險與挑戰
    • 研發檢測技術成本高昂
    • 意識水平低
  • 機會
    • 擴大即時檢測和快速內分泌檢測的範圍
• 成長潛力分析
• 監理情勢
• 技術與創新趨勢（基於初步調查）
  • 當前技術趨勢
  • 新興技術
• 未來市場趨勢（基於初步研究）
• 人工智慧和生成式人工智慧對市場的影響（基於初步研究）
• 2025年價格分析
• 專利分析
• 消費者洞察
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業矩陣分析
• 企業市佔率分析（基於初步研究）
  • 世界
  • 北美洲
  • 歐洲
  • 亞太地區
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係與合作
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依測試類型分類，2022-2035年

• 人類絨毛膜促性腺激素分泌(hCG) 荷爾蒙檢測
• 甲狀腺刺激素（TSH）檢測
• 胰島素測試
• 孕酮測試
• 黃體激素(LH) 檢測
• 催乳素試驗
• 其他類型的測試

第6章 市場估計與預測：依技術分類，2022-2035年

• 免疫檢測
• 質譜分析
• 層析法
• 基於核酸的
• 其他技術

第7章 市場估計與預測：依最終用途分類，2022-2035年

• 臨床檢查室
• 醫院
• 診斷中心
• 其他最終用戶

第8章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Abbott
• Autobio
• BECKMAN COULTER
• BIO RAD
• Diasorin
• DRG International
• Merck
• Monobind
• QuidelOrtho
• Roche
• SCIEX
• SIEMENS Healthineers
• Snibe Diagnostic
• Thermo Fisher SCIENTIFIC
• TOSOH BIOSCIENCE

The Global Endocrine Testing Market was valued at USD 3.4 billion in 2025 and is estimated to grow at a CAGR of 8.2% to reach USD 7.4 billion by 2035.

The industry is expanding steadily due to the rising burden of hormonal disorders, including metabolic and gland-related conditions, along with increasing awareness regarding early diagnosis and preventive healthcare. Growing emphasis on routine screening and disease monitoring is encouraging higher adoption of diagnostic testing across healthcare systems. In addition, continuous government support through funding programs and healthcare initiatives is strengthening testing accessibility and infrastructure development. Expanding healthcare expenditure, coupled with advancements in diagnostic technologies, is further enhancing testing accuracy and efficiency. The integration of automated systems and improved laboratory capabilities is enabling faster turnaround times and large-scale testing volumes. Increasing focus on personalized healthcare and long-term disease management is also contributing to the sustained demand for endocrine diagnostics. These combined factors are positioning the endocrine testing market for consistent growth across both developed and emerging economies.

Endocrine testing encompasses a variety of laboratory-based diagnostic procedures used to evaluate hormonal balance and glandular function within the body. These tests measure hormone levels and related biomarkers to support the diagnosis and monitoring of endocrine system conditions. Growing investments in healthcare infrastructure and public health programs are improving access to diagnostic services, particularly in regions with limited resources. Increased focus on early detection and preventive care is encouraging wider use of hormone testing across healthcare facilities. Government-backed screening initiatives and funding support for diagnostic laboratories are further contributing to the expansion of testing services, strengthening overall market growth.

The human chorionic gonadotropin testing segment accounted for 31.1% share in 2025. This segment maintains a leading position due to its widespread clinical use and growing preference for rapid and minimally invasive diagnostic approaches. High testing volumes across healthcare settings and strong demand for convenient diagnostic solutions continue to support its dominance in the endocrine testing market.

The immunoassay segment is anticipated to grow at a CAGR of 7.7%, reaching USD 2.8 billion by 2035. This technology remains a preferred choice due to its high sensitivity, accuracy, and cost efficiency. Its compatibility with automated systems and ability to handle large testing volumes are key factors driving its adoption. Continuous technological advancements and broad acceptance across diagnostic laboratories further reinforce its importance within the market.

North America Endocrine Testing Market generated USD 1.5 billion in 2025 and is expected to witness significant growth throughout the forecast period. The region benefits from well-established healthcare infrastructure, strong adoption of advanced diagnostic technologies, and high demand for routine and specialized testing. Increasing healthcare awareness, along with supportive reimbursement frameworks and access to modern diagnostic platforms, continues to sustain consistent testing demand across the region.

Key players operating in the Global Endocrine Testing Market include Thermo Fisher Scientific, Roche, Abbott, Siemens Healthineers, Beckman Coulter, Bio-Rad, Merck, Diasorin, SCIEX, Snibe Diagnostic, Autobio, DRG International, Monobind, Tosoh Bioscience, and QuidelOrtho. Companies in the Endocrine Testing Market are focusing on strengthening their competitive position through continuous investment in advanced diagnostic technologies and automation. They are prioritizing research and development to enhance test accuracy, sensitivity, and efficiency while reducing turnaround time. Strategic collaborations, partnerships, and acquisitions are being leveraged to expand geographic reach and diversify product portfolios. Firms are also emphasizing the development of cost-effective and high-throughput solutions to meet increasing demand across healthcare facilities.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy & data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail & confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Test type trends
  • 2.2.3 Technology trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of diabetes, thyroid, and obesity
    • 3.2.1.2 Rising prevalence of endocrine disorders
    • 3.2.1.3 Supportive government funding initiatives
    • 3.2.1.4 Technological advancements
    • 3.2.1.5 Growing awareness of routine health monitoring
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost for the development of testing technologies
    • 3.2.2.2 Lack of awareness
  • 3.2.3 Opportunities
    • 3.2.3.1 Expansion of point-of-care and rapid endocrine testing
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Technology and innovation landscape (Driven by Primary Research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Impact of AI & Generative AI on the Market (Driven by Primary Research)
• 3.8 Pricing analysis, 2025
• 3.9 Patent analysis
• 3.10 Consumer insights
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by Primary Research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Human chorionic gonadotropin (hCG) hormone test
• 5.3 Thyroid stimulating hormone (TSH) test
• 5.4 Insulin test
• 5.5 Progesterone test
• 5.6 Luteinizing hormone (LH) test
• 5.7 Prolactin test
• 5.8 Other test types

Chapter 6 Market Estimates and Forecast, By Technology, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Immunoassay
• 6.3 Mass spectroscopy
• 6.4 Chromatography
• 6.5 Nucleic acid based
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Clinical laboratories
• 7.3 Hospitals
• 7.4 Diagnostic centers
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 Autobio
• 9.3 BECKMAN COULTER
• 9.4 BIO RAD
• 9.5 Diasorin
• 9.6 DRG International
• 9.7 Merck
• 9.8 Monobind
• 9.9 QuidelOrtho
• 9.10 Roche
• 9.11 SCIEX
• 9.12 SIEMENS Healthineers
• 9.13 Snibe Diagnostic
• 9.14 Thermo Fisher SCIENTIFIC
• 9.15 TOSOH BIOSCIENCE